STAAR Surgical Company (NASDAQ: STAA) sees a slight market movement with updated stock metrics, offering investors fresh insight into its position and operational context.
Company Overview
Founded in 1982 and headquartered in Lake Forest, California, STAAR Surgical Company designs, develops, manufactures, markets, and sells implantable lenses for the eye along with companion delivery systems. Its Visian implantable Collamer lens product family addresses myopia, hyperopia, astigmatism, and presbyopia. The product offerings also include preloaded silicone cataract intraocular lenses and injector systems for cataract surgery, along with related instruments.
The company reaches global markets through direct sales representatives in the United States, Japan, Germany, Spain, Canada, the UK, and Singapore, and through independent distributors in China, Korea, India, France, Benelux, Italy, and other regions. Customers include ophthalmic surgeons, vision centers, hospitals, and government facilities.
Stock Performance
STAAR Surgical shares are currently trading at USD 26.67, reflecting a minor decrease of USD 0.05, or -0.19% compared to the previous session. This movement is within its 52-week range of USD 13.50 to USD 33.28.
The market capitalization stands at approximately USD 1.32 billion. This metric is significant for investors as it places STAA in the mid-cap category, suggesting moderate stability with growth potential. Current trading volume is 905,269 shares, which is below the average daily volume of 1,564,503 shares, possibly indicating less short-term trading activity.
STAAR Surgical does not currently distribute dividends, meaning returns to shareholders are dependent on capital appreciation rather than income payouts.
Market Position and Sector
Operating within the medical instruments and supplies industry, STAAR Surgical competes in the healthcare sector, focusing on vision correction technologies. Its position is defined by specialty products aimed at ophthalmologists and surgical centers. In an industry where innovation directly influences competitive advantage, the company’s niche focus on implantable lens technologies offers differentiation from broader healthcare device manufacturers.
Governance and Leadership
Stephen C. Farrell CFA leads the company as Chief Executive Officer. Leadership stability and experience in both corporate governance and finance are important for navigating regulatory demands, managing innovation pipelines, and maintaining investor confidence.
The company employs 1,157 full-time staff, a scale that supports its global distribution and manufacturing operations without being overly large. This size potentially allows for agility in responding to market shifts.
Key Financial Data
Price: USD 26.67
Market Cap: USD 1,321,550,053
Last Dividend: 0
52-week Range: USD 13.50 – USD 33.28
Change: -0.05
Change %: -0.18713%
Volume: 905,269
Average Volume: 1,564,503
For investors, the absence of a dividend can indicate reinvestment of earnings into growth strategies. The relatively narrow recent price movement may signal market stability or a consolidation phase. Volume trends can suggest interest levels, and below-average current volume might reflect reduced near-term trading momentum.
Trading Details:
Exchange: NASDAQ Global Market
Ticker: STAA
ISIN: US8523123052
CUSIP: 852312305
IPO Date: February 24, 1992
Actively Trading: Yes
FAQ
- Does STAAR Surgical pay dividends?
No, the company has a last recorded dividend of 0, indicating no current payout policy. - Where is STAAR Surgical traded?
It is listed on the NASDAQ Global Market under ticker STAA. - How many employees does STAAR Surgical have?
The company reports 1,157 full-time employees. - What is the main product focus?
Implantable lenses for vision correction and related delivery systems.
Conclusion
STAAR Surgical presents a focused business model in a highly specialized healthcare niche. Current stock metrics suggest stability with moderate changes in price and volume. Investors may find value in monitoring innovation pipelines and expansion in global markets for signals on growth potential.
Disclaimer
This content is for informational purposes only. It does not constitute investment advice, recommendation, or solicitation of securities.
Announcement
For full information about the company, see the link below.
https://www.staar.com